Clinical and laboratory features of patients and controls
| . | VT, n = 19 . | PM, n = 8 . | HC, n = 23 . |
|---|---|---|---|
| Age, mean ± SEM, y | 47.3 ± 3.3 | 42.1 ± 2.0 | 38 ± 4.8 |
| Sex | 15 F/4 M | 8 F | 16 F/7 M |
| PAPS (%) | 9 (47.3) | 7 (88) | 0 |
| SLE (%) | 10 (53) | 1 (12) | 0 |
| Live births | 9 | 13 | 6 |
| Total APS-related PM | 0 | 8 (7 ST-PL, 1 TT-PL) | 0 |
| VT | 12 V, 11 A, 5 R | 0 | 0 |
| Other disease features | haem 8, arth 8, muc 7, neuro 6, serositis 4, renal 3 | 0* | 0 |
| Serum LA-positive | 13 | 6 | NT |
| Serum aCL, mean GPLU ± SEM | 143.6 ± 19.2 | 113.0 ± 18.3 | 9.1 ± 0.8 |
| Serum anti-b2GPI, mean GDU ± SEM | 86.1 ± 19.5 | 72.3 ± 26.3 | 12 ± 0.4 |
| IgG aCL, mean GPLU ± SEM | 101.7 ± 16.7 | 76.4 ± 19.8 | 7.5 ± 0.5 |
| IgG anti-b2GPI, mean GDU ± SEM | 57.1 ± 12.5 | 64.7 ± 33.3 | 9.5 ± 0.5 |
| Other autoantibodies | anti-dsDNA 8, anti-Ro 4, anti-La 2, anti-RNP 2 | 0* | 0 |
| Medication | OA 19, CS 5, HCQ 4, AZA 3, LDA 2, MMF 1 | LDA 7, HCQ 2* | 0 |
| . | VT, n = 19 . | PM, n = 8 . | HC, n = 23 . |
|---|---|---|---|
| Age, mean ± SEM, y | 47.3 ± 3.3 | 42.1 ± 2.0 | 38 ± 4.8 |
| Sex | 15 F/4 M | 8 F | 16 F/7 M |
| PAPS (%) | 9 (47.3) | 7 (88) | 0 |
| SLE (%) | 10 (53) | 1 (12) | 0 |
| Live births | 9 | 13 | 6 |
| Total APS-related PM | 0 | 8 (7 ST-PL, 1 TT-PL) | 0 |
| VT | 12 V, 11 A, 5 R | 0 | 0 |
| Other disease features | haem 8, arth 8, muc 7, neuro 6, serositis 4, renal 3 | 0* | 0 |
| Serum LA-positive | 13 | 6 | NT |
| Serum aCL, mean GPLU ± SEM | 143.6 ± 19.2 | 113.0 ± 18.3 | 9.1 ± 0.8 |
| Serum anti-b2GPI, mean GDU ± SEM | 86.1 ± 19.5 | 72.3 ± 26.3 | 12 ± 0.4 |
| IgG aCL, mean GPLU ± SEM | 101.7 ± 16.7 | 76.4 ± 19.8 | 7.5 ± 0.5 |
| IgG anti-b2GPI, mean GDU ± SEM | 57.1 ± 12.5 | 64.7 ± 33.3 | 9.5 ± 0.5 |
| Other autoantibodies | anti-dsDNA 8, anti-Ro 4, anti-La 2, anti-RNP 2 | 0* | 0 |
| Medication | OA 19, CS 5, HCQ 4, AZA 3, LDA 2, MMF 1 | LDA 7, HCQ 2* | 0 |
A, arterial; aCL, anti-cardiolipin antibody; anti-β2GPI, anti-β2-glycoprotein-I antibody; arth, arthritis; AZA, azathioprine; CS, corticosteroid; dsDNA, double stranded DNA; F, female; GDU, IgG arbitrary unit; GPI, glycoprotein I; GPLU, IgG phospholipid unit; haem, hematological; HCQ, hydroxychloroquine; LDA, low-dose aspirin; M, male; MMF, mycophenolate mofetil; muc, mucocutaneous; neuro, neurological; NT, not tested; OA, oral anticoagulant; PAPS, primary APS; PM, pregnancy morbidity; R, recurrent; RNP, ribonucleoprotein; SEM, standard error of the mean; ST-PL, second-trimester pregnancy loss; TIA, transient ischemic attack; TT-PL, third-trimester pregnancy loss; V venous.
Incomplete information on SLE of patient with SLE/APS.